Related Experiment Videos
[Evaluation of bacterial resistance to pefloxacine after prolonged use in resuscitation]
P Malacarne1, S Casagli, P Kaisserli
12. Servizio di Anestesia e Rianimazione, USL n. 12, Ospedale S. Chiara, Pisa.
Abstract:
In an overall of the value of an antibiotic it is important to take into account the onset of bacterial resistance in addition to its immediate clinical effects since the former can render an otherwise efficacious antibiotic obsolete within a short space of time. We studied two groups of intubated patients with pneumonia infections during two different periods in 1990: January-June and October-December; each patient was treated with pefloxacin 400 mg twice a day i.v. for 6 days on the basis of an antibiogram carried out on tracheobronchial secretion; at the end of that period patients were clinically evaluated and a second bacteriological test was performed. It was found that the percentage of pefloxacin-resistant bacterial strains did not increase significantly after this antibiotic had been used for a year for pneumonia infections (from 27.5% to 33%). The appearance of bacterial resistance at the six-day treatment cycle was similar in both groups (19% and 22%). Of all the bacterial strains, Pseudomonas aeruginosa showed the greatest tendency to become resistant.
Insights
Peffloxacin remains effective for pneumonia infections, as bacterial resistance did not significantly increase after one year of use. Resistance during a six-day treatment cycle was also consistent across study periods.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Context:
- Antibiotic efficacy is challenged by emerging bacterial resistance.
- Pneumonia infections in intubated patients require effective antibiotic treatment.
- Monitoring antibiotic resistance is crucial for public health.
Purpose:
- To evaluate the clinical value of pefloxacin for pneumonia infections.
- To assess the development of bacterial resistance to pefloxacin over time.
- To compare resistance rates during different treatment periods.
Summary:
- A study investigated pefloxacin's efficacy in intubated pneumonia patients over two periods in 1990.
- Patients received 400 mg IV pefloxacin twice daily for six days, guided by antibiograms.
- Peffloxacin-resistant bacterial strains increased slightly from 27.5% to 33% after one year, with no significant difference in resistance during the six-day treatment cycle (19% vs. 22%).
- Pseudomonas aeruginosa exhibited the highest resistance tendency.
Impact:
- Peffloxacin demonstrated sustained clinical value for pneumonia treatment despite initial resistance levels.
- The study highlights the importance of continuous monitoring of antibiotic resistance patterns.
- Findings inform clinical guidelines for antibiotic stewardship in respiratory infections.